JP2022551751A5 - - Google Patents

Info

Publication number
JP2022551751A5
JP2022551751A5 JP2022522586A JP2022522586A JP2022551751A5 JP 2022551751 A5 JP2022551751 A5 JP 2022551751A5 JP 2022522586 A JP2022522586 A JP 2022522586A JP 2022522586 A JP2022522586 A JP 2022522586A JP 2022551751 A5 JP2022551751 A5 JP 2022551751A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
decreased
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022522586A
Other languages
English (en)
Japanese (ja)
Other versions
JP7809056B2 (ja
JP2022551751A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056121 external-priority patent/WO2021076991A1/en
Publication of JP2022551751A publication Critical patent/JP2022551751A/ja
Publication of JP2022551751A5 publication Critical patent/JP2022551751A5/ja
Priority to JP2025171716A priority Critical patent/JP2026028257A/ja
Application granted granted Critical
Publication of JP7809056B2 publication Critical patent/JP7809056B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022522586A 2019-10-17 2020-10-16 血液障害を処置するための組成物及び方法 Active JP7809056B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171716A JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916492P 2019-10-17 2019-10-17
US62/916,492 2019-10-17
PCT/US2020/056121 WO2021076991A1 (en) 2019-10-17 2020-10-16 Compositions and methods for treating blood disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171716A Division JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022551751A JP2022551751A (ja) 2022-12-13
JP2022551751A5 true JP2022551751A5 (https=) 2023-10-24
JP7809056B2 JP7809056B2 (ja) 2026-01-30

Family

ID=75538375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022522586A Active JP7809056B2 (ja) 2019-10-17 2020-10-16 血液障害を処置するための組成物及び方法
JP2025171716A Pending JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171716A Pending JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240109957A1 (https=)
EP (1) EP4045084A4 (https=)
JP (2) JP7809056B2 (https=)
KR (1) KR20220083737A (https=)
CN (1) CN114746118A (https=)
AU (1) AU2020365132A1 (https=)
BR (1) BR112022007051A2 (https=)
CA (1) CA3157873A1 (https=)
IL (1) IL292186A (https=)
MX (1) MX2022004287A (https=)
WO (1) WO2021076991A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
CA3195798A1 (en) * 2020-10-16 2022-04-21 Ted Yednock Compositions and methods for treating blood disorders
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN118259018B (zh) * 2024-03-21 2024-10-29 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用
CN119371528B (zh) * 2024-10-30 2025-06-24 泰州市人民医院 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
ES2589912T3 (es) * 2008-04-02 2016-11-17 Macrogenics, Inc. Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
DK3019240T3 (da) * 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
SI3215527T1 (sl) * 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Similar Documents

Publication Publication Date Title
JP2022551751A5 (https=)
US10618976B2 (en) SIRP-α agonist antibody
JP6244350B2 (ja) ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
CA2869477C (en) Humanized and chimeric anti-factor c3 antibodies and uses thereof
JP2018520139A (ja) エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
KR102896085B1 (ko) 인자 h 강화 항체 및 이의 사용
JP2020511469A5 (https=)
KR20130036276A (ko) 보체 결합 3의 C3d 조각에 대한 항체들
CN111630065A (zh) 抗c5抗体组合及其用途
JP2019513726A5 (https=)
JP2023545501A5 (https=)
EP3532497B1 (en) Modified immunoglobulin hinge regions to reduce hemagglutination
CN103068396A (zh) 使用抑制c5和备解素相互作用的抗-备解素抗体来抑制交替途径介导的症患的方法
JP6965157B2 (ja) Ｈ因子を強化する抗体及びその用途
CN114828886A (zh) 因子h增强抗体及其用途
JP2023526051A (ja) 発作性夜間ヘモグロビン尿症の処置のための補体ｄ因子阻害剤の単独又は抗ｃ５抗体との組み合わせでの使用
JP7735545B2 (ja) Ｃｄｃプラットホーム抗体
JP6737482B1 (ja) 抗ポドプラニン抗体
WO2007002571A2 (en) Use of an anti c5 complement antibody to treat patients with sickle cell disease
KR20250077505A (ko) 항-c1q 항체를 위한 제형
JP2023507852A5 (https=)
JP2024545741A (ja) 単一特異性および二重特異性抗体ならびにその抗原結合断片
HK40109959A (zh) 使用激活素受体ii型信号传导抑制剂的方法
TH1801007665A (th) แอนติ-c5 แอนติบอดี และการใช้สิ่งนี้